Loss of RBM-26 causes mitochondria dysfunction in PLM. by Tamjid A. Chowdhury (14149846)

RBM-26 is expressed in the PLM and functions within neurons to protect against axon degeneration and prevent axon overlap defects. by Tamjid A. Chowdhury (14149846)

Mutations in <i>rbm-26</i> cause axon degeneration and axon overlap defects. by Tamjid A. Chowdhury (14149846)

Loss of MALS-1 function suppresses the mitochondrial and axon degeneration phenotypes that are caused by loss of RBM-26 function. by Tamjid A. Chowdhury (14149846)

Loss of RBM-26 function causes a reduction in the density of mitochondria in the PLM axon. by Tamjid A. Chowdhury (14149846)

Sensitivity analysis. by Ying Zhao (16546)

Scatter plot of MR analysis. by Ying Zhao (16546)

Associations between ISSNHL and the serum 25-hydroxyvitamin D level. by Ying Zhao (16546)

Heterogeneity testing of IVs for the serum 25-hydroxyvitamin D level. by Ying Zhao (16546)

The forest plots illustrating the estimated causal effects of individual SNPs. by Ying Zhao (16546)

Associations between the serum 25-hydroxyvitamin D level and risk of idiopathic sudden sensorineural hearing loss. by Ying Zhao (16546)

Design of the MR study on the causal relationship between serum 25(OH)D levels and ISSNHL. by Ying Zhao (16546)

Heterogeneity analysis. by Ying Zhao (16546)

Reverse MR analysis data. by Ying Zhao (16546)

SNP dressing by screening. by Ying Zhao (16546)

Co-transformed cells grow preferentially as tumors in peritoneal cavities. by Mitchell Hayes (5334887)

Expression of RBM-26 is disrupted by P80L and L13V missense mutations. by Tamjid A. Chowdhury (14149846)

Initial RBC dominant clot compaction in the <i>in vitro</i> MCA model without and with collateral with alteplase applied at clinically relevant concentration (1.3 mg L^-1... by Sandra Thalerová (11434762)

Results for fibrin dominant clots: (A) time to recanalize <i>in vitro</i> model; (B) relative clot reduction; (C) RBC release; (D) relative clot degradation rate. by Sandra Thalerová (11434762)

Clinical characteristics of the study population. by Hun Gi Lee (21526538)

“…The total number of patients who met with P-TAs was 26,842, with a 43.1% reduction from 17,105–9,737. A decrease was observed across all age groups; however, the rate was lower in the geriatric and severely injured groups. …”